세계의 임상시험 용품 시장 규모, 점유율, 동향 분석 보고서 : 임상 단계별, 제품 및 서비스별, 최종 용도별, 치료 분야별, 지역별, 부문 예측(2025-2030년)

Clinical Trial Supplies Market Size, Share & Trends Analysis Report By Clinical Phase (Phase I, Phase II, Phase III), By Product & Services, By End Use, By Therapeutic Area, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,311,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,708,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,502,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

임상시험 용품 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 임상시험 용품 시장 규모는 2030년에 41억 달러에 달할 것으로 추정되며, 2025-20305년 7.19%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다.

임상시험량 증가와 시험 수행의 복잡성은 시장 성장을 가속하는 주요 요인 중 하나입니다.

세계적으로 만성질환의 유병률 증가와 급속한 고령화는 생물학적 제제 연구개발의 성장을 가속할 것으로 예상되며, 효율적인 임상 공급품에 대한 수요를 더욱 촉진하여 임상시험 공급품 산업의 성장에 기여할 것으로 예측됩니다. 또한, 희귀질환 치료제 수요 증가와 희귀질환 연구개발에 대한 높은 투자도 생물학적 제제 개발에 기여할 것으로 예측됩니다. 이러한 요인으로 인해 이 부문은 예측 기간 동안 큰 성장을 이룰 가능성이 높습니다.

예를 들어, 2022년 노바티스는 연구개발에 약 100억 달러를 투자했습니다. 또한 유럽연합(EU), 일본, 중국, 미국 등에서 23건의 신약 및 희귀질환에 대한 승인을 획득했습니다. 인도에서는 비정형 용혈성요독증후군(aHUS), 면역성 혈소판감소성 자반병(ITP), 척수성 근위축증(SMA), 루푸스 신염 등 희귀질환에서 17개의 임상 프로그램을 진행하고 있으며, 44개의 진행 중인 임상 3상 프로그램을 진행하고 있습니다.

DTP(Direct-to-Patient)는 임상시험용 의약품의 유통에 있어 앞으로의 유통 모델로 기대되는 분야로, 환자에게 직접 약물을 전달하여 환자 중심의 임상시험을 진행하는 새로운 모델 중 하나입니다. 코로나19 사태는 최소한의 혼란으로 임상시험 연구를 지속하기 위해 이러한 모델의 채택을 증가시키는 계기가 되었으며, 이는 임상시험 시설 방문 횟수를 줄여 참가자의 부담을 줄여줍니다. 또한, 환자 유지와 전 세계의 다양한 환자 풀은 이 모델의 높은 채택률에 기인하는 두드러진 이유 중 일부입니다.

임상시험 용품 시장 보고서 하이라이트

• 임상 단계별로는 2024년 임상 3상 시험이 53.03%의 매출 점유율을 차지하며 시장을 주도했습니다. 현재 임상 3상 단계에 있는 분자가 많다는 점이 매출 감소의 주요 원인으로 작용하고 있습니다.
• 서비스 중에서는 보관 및 유통 분야가 예측 기간 동안 CAGR 7.54%로 가장 빠르게 성장할 것으로 예측됩니다. 세계 바이오의약품 파이프라인 증가와 온도에 민감한 의약품 증가로 인해 임상시험용 의약품의 물류에 대한 복잡성이 증가할 것으로 예측됩니다.
• 생물학적 제제는 나노 입자 기반 약물 전달 시스템 개발 등 유전학 및 생명공학 분야의 연구 증가로 인해 예측 기간 동안 CAGR 7.48%로 가장 빠르게 성장할 것으로 예측됩니다.
• United Press International에 따르면, 미국 병원에서는 부적절한 투여로 인해 수십억 개의 항암제 바이알이 폐기되고 있으며, 적절한 공급 관리가 필요하다는 지적이 제기되고 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 임상시험 용품 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상위 시장 전망
  • 관련/보조 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 기술 진보
  • AI와 디지털 기술 통합
• 가격 모델 분석
• 임상시험 건수 분석, 2024년
  • 지역별 임상시험 총수(2024년)
  • 임상시험 총수(단계별)(2024년)
  • 임상시험 총수(연구 디자인별)(2024년)
  • 주요 치료 영역별 임상시험 총수(2024년)
• 시장 분석 툴
  • Porter의 Five Forces 분석
  • SWOT 분석에 의한 PESTEL
  • COVID-19의 영향 분석

제4장 임상시험 용품 시장 : 임상 단계별 추정 및 동향 분석

• 임상시험 용품 시장(임상 단계별) : 부문 대시보드
• 임상시험 용품 시장(임상 단계별) : 변동 분석
• 임상 단계별, 2018년-2030년
• Phase I
• Phase II
• Phase III
• 기타

제5장 임상시험 용품 시장 : 제품 및 서비스별 추정 및 동향 분석

• 임상시험 용품 시장(제품 및 서비스별) : 부문 대시보드
• 임상시험 용품 시장(제품 및 서비스별) : 변동 분석
• 제품 및 서비스별, 2018년-2030년
• 제조업
  • 임상시험 용품 제조 시장 추정과 부문 예측, 2018년-2030년
  • 보관 및 배송
  • 공급망 관리

제6장 임상시험 용품 시장 : 치료 영역별 추정 및 동향 분석

• 임상시험 용품 시장(치료 영역별) : 부문 대시보드
• 임상시험 용품 시장(치료 영역별) : 변동 분석
• 치료 영역별, 2018년-2030년
• 종양학
• 중추신경계 질환
• 심혈관질환
• 감염증
• 대사장애
• 기타

제7장 임상시험 용품 시장 : 최종 용도별 추정 및 동향 분석

• 임상시험 용품 시장(최종 용도별) : 부문 대시보드
• 임상시험 용품 시장(최종 용도별) : 변동 분석
• 용도별, 2018년-2030년
• 의약품
• 생물학적 제제
• 의료기기
• 기타

제8장 임상시험 용품 시장 : 지역별 추정 및 동향 분석

• 지역별 시장 점유율 분석, 2024년 및 2030년
• 지역 시장 대시보드
• 세계 지역 시장 스냅숏
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제9장 경쟁 구도

• 기업 분류
  • 시장 리더
  • 신규 기업
• 기업 개요
  • Almac Group
  • Biocair
  • Catalent, Inc.
  • KLIFO
  • Movianto
  • PCI Pharma Services
  • Sharp Services, LLC
  • Thermo Fisher Scientific, Inc.
  • UPS Healthcare
  • Paraxel International Corporation

LSH

영문 목차

영문목차

Clinical Trial Supplies Market Growth & Trends:

The global clinical trial supplies market size is estimated to reach USD 4.10 billion in 2030 and is anticipated to grow at a compound annual growth rate CAGR of 7.19% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing volume of clinical trial studies coupled with the growing complexity in conduction of these trials are some of the major factors driving the market growth.

Globally, an increase in the prevalence of chronic diseases and the rapidly aging population are expected to drive the growth of R&D of biologics, which is expected to further propel the demand for efficient clinical supplies and contribute to the growth of the clinical trial supplies industry. Furthermore, an increase in the demand for orphan drugs and high investment in the R&D of rare diseases are also expected to contribute toward the development of biologic drugs. Thus, owing to these factors, this segment is likely to witness significant growth during the forecast period.

For instance, in 2022, Novartis invested around USD 10 billion in research and development. It also secured 23 approvals in the European Union, Japan, China, and the U.S. for new drugs and rare diseases. The company is also conducting 44 ongoing phase III programs in India with 17 clinical programs running in rare diseases such as atypical hemolytic uremic syndrome (aHUS), Immune thrombocytopenic purpura (ITP), spinal muscular atrophy (SMA), and Lupus Nephritis.

Direct-to-Patients (DTP) is an upcoming segment in the distribution of clinical trial supplies, which is expected to be the future model of distribution. DTP is one of the emerging models that involves delivering drugs to patients directly to create patient-centric trials. This would facilitate fewer visits to the site and reduce the burden on participants. The COVID-19 outbreak has led to the increased adoption of such a model, to continue clinical trial studies with minimum disruption. In addition, patient retention and a diverse pool of patients worldwide are some of the notable reasons that can be attributed to the high adoption of this model.

Clinical Trial Supplies Market Report Highlights:

• Based on the clinical phase, the market is anticipated to be dominated by the Phase III trial segment with a 53.03% revenue share in 2024. The presence of a large number of molecules currently under Phase III makes it the primary factor responsible for this deduction
• Among services, the storage, and distribution segment is anticipated to witness the fastest growth at a CAGR of 7.54% during the forecast period. The rise in global biologics pipeline and temperature-sensitive drugs is expected to increase the complexities related to the logistics of clinical trial supplies
• Biologics are expected to witness the fastest growth at 7.48% CAGR during the forecast period owing to the increasing research in the field of genetics and biotechnology such as the development of nanoparticle-based drug delivery systems
• In terms of therapeutic use, oncology dominated the market with a revenue share of 39.59% in 2024. According to the United Press International, hospitals in the U.S. are disposing of billions of cancer drug vials due to improper dosage, thereby indicating the need for appropriate supply management

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Regional Scope
  • 1.1.2. Estimates and Forecast Timeline
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Purchased Database
  • 1.3.3. GVR's Internal Database
  • 1.3.4. Secondary Sources
  • 1.3.5. Primary Research
• 1.4. Information or Data Analysis
  • 1.4.1. Data Analysis Models
• 1.5. Market Formulation & Validation
  • 1.5.1. Region Wise Market: Base Estimates
  • 1.5.2. Global Market: CAGR Calculation
• 1.6. Model Details
  • 1.6.1. Commodity Flow Analysis (Model 1)
  • 1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
  • 1.6.3. QFD Model Sizing & Forecasting (Model 3)
  • 1.6.4. Bottom-Up Approach (Model 4)
• 1.7. List of Secondary Sources
• 1.8. List of Abbreviations
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Regulatory Framework

Chapter 3. Clinical Trial Supplies Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Drivers Analysis
    • 3.2.1.1. Expansion of Clinical Trials Sites
    • 3.2.1.2. Growing R&D in Biologics and Biosimilars
    • 3.2.1.3. Advancements in Supply Chain Technology
  • 3.2.2. Market Restraints Analysis
    • 3.2.2.1. Presence of Stringent Regulatory Policies
    • 3.2.2.2. High Possibility of Counterfeiting Drugs
• 3.3. Technological Advancements
  • 3.3.1. Integration of AI and Digital Technologies
• 3.4. Pricing Model Analysis
• 3.5. Clinical Trials Volume Analysis, 2024
  • 3.5.1. Total Number of Clinical Trials, by Region (2024)
  • 3.5.2. Total Number of Clinical Trials, by Phase (2024)
  • 3.5.3. Total Number of Clinical Trials, by Study Design (2024)
  • 3.5.4. Total Number of Clinical Trials, by Key Therapeutic Area (2024)
• 3.6. Market Analysis Tools
  • 3.6.1. Porter's Five Forces Analysis
  • 3.6.2. PESTEL by SWOT Analysis
  • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Clinical Trial Supplies Market: Clinical Phase Estimates & Trend Analysis

• 4.1. Clinical Trial Supplies Market, By Clinical Phase: Segment Dashboard
• 4.2. Clinical Trial Supplies Market, By Clinical Phase: Movement Analysis
• 4.3. Clinical Trial Supplies Market Estimates & Forecasts, By Clinical Phase, 2018 - 2030 (USD Million)
• 4.4. Phase I
  • 4.4.1. Phase I Clinical Trial Supplies Market Estimates and Segment Forecasts, 2018 - 2030 (USD Million)
• 4.5. Phase II
  • 4.5.1. Phase II Clinical Trial Supplies Market Estimates and Segment Forecasts, 2018 - 2030 (USD Million)
• 4.6. Phase III
  • 4.6.1. Phase III Clinical Trial Supplies Market Estimates and Segment Forecasts, 2018 - 2030 (USD Million)
• 4.7. Others
  • 4.7.1. Others Clinical Trial Supplies Market Estimates and Segment Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Clinical Trial Supplies Market: Product & Service Estimates & Trend Analysis

• 5.1. Clinical Trial Supplies Market, By Product & Service: Segment Dashboard
• 5.2. Clinical Trial Supplies Market, By Product & Service: Movement Analysis
• 5.3. Clinical Trial Supplies Market Estimates & Forecasts, By Product & Service, 2018 - 2030 (USD Million)
• 5.4. Manufacturing
  • 5.4.1. Manufacturing Clinical Trial Supplies Market Estimates and Segment Forecasts, 2018 - 2030 (USD Million)
  • 5.4.2. Storage & Distribution
    • 5.4.2.1. Downstream processing Clinical Trial Supplies Market Estimates and Segment Forecasts, 2018 - 2030 (USD Million)
    • 5.4.2.2. Cold Chain Distribution
      • 5.4.2.2.1. Cold Chain Distribution Clinical Trial Supplies Market Estimates and Segment Forecasts, 2018 - 2030 (USD Million)
    • 5.4.2.3. Non-Cold Chain Distribution
      • 5.4.2.3.1. Non-Cold Chain Distribution Clinical Trial Supplies Market Estimates and Segment Forecasts, 2018 - 2030 (USD Million)
  • 5.4.3. Supply Chain Management
    • 5.4.3.1. Supply Chain Management Clinical Trial Supplies Market Estimates and Segment Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Clinical Trial Supplies Market: Therapeutic Area Estimates & Trend Analysis

• 6.1. Clinical Trial Supplies Market, By Therapeutic Area: Segment Dashboard
• 6.2. Clinical Trial Supplies Market, By Therapeutic Area: Movement Analysis
• 6.3. Clinical Trial Supplies Market Estimates & Forecasts, By Therapeutic Area, 2018 - 2030 (USD Million)
• 6.4. Oncology
  • 6.4.1. Oncology Clinical Trial Supplies Market Estimates and Segment Forecasts, 2018 - 2030 (USD Million)
• 6.5. CNS Diseases
  • 6.5.1. CNS Diseases Clinical Trial Supplies Market Estimates and Segment Forecasts, 2018 - 2030 (USD Million)
• 6.6. Cardiovascular Diseases
  • 6.6.1. Cardiovascular Diseases Clinical Trial Supplies Market Estimates and Segment Forecasts, 2018 - 2030 (USD Million)
• 6.7. Infectious Disease
  • 6.7.1. Infectious Disease Clinical Trial Supplies Market Estimates and Segment Forecasts, 2018 - 2030 (USD Million)
• 6.8. Metabolic Disorders
  • 6.8.1. Metabolic Disorders Clinical Trial Supplies Market Estimates and Segment Forecasts, 2018 - 2030 (USD Million)
• 6.9. Others
  • 6.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 7. Clinical Trial Supplies Market: End Use Estimates & Trend Analysis

• 7.1. Clinical Trial Supplies Market, By End Use: Segment Dashboard
• 7.2. Clinical Trial Supplies Market, By End Use: Movement Analysis
• 7.3. Clinical Trial Supplies Market Estimates & Forecasts, By End Use, 2018 - 2030 (USD Million)
• 7.4. Pharmaceutical
  • 7.4.1. Pharmaceutical Clinical Trial Supplies Market Estimates and Segment Forecasts, 2018 - 2030 (USD Million)
• 7.5. Biologics
  • 7.5.1. Oncology Clinical Trial Supplies Market Estimates and Segment Forecasts, 2018 - 2030 (USD Million)
• 7.6. Medical Devices
  • 7.6.1. Medical Devices Clinical Trial Supplies Market Estimates and Segment Forecasts, 2018 - 2030 (USD Million)
• 7.7. Others
  • 7.7.1. Others Clinical Trial Supplies Market Estimates and Segment Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Clinical Trial Supplies Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2024 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Global Regional Market Snapshot
• 8.4. North America
  • 8.4.1. North America Clinical Trial Supplies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. U.S. Clinical Trial Supplies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Canada Clinical Trial Supplies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Mexico Clinical Trial Supplies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.5. Europe
  • 8.5.1. Europe Clinical Trial Supplies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. UK Clinical Trial Supplies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Germany Clinical Trial Supplies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. France Clinical Trial Supplies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Italy Clinical Trial Supplies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Spain Clinical Trial Supplies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.7. Denmark
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Denmark Clinical Trial Supplies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.8. Sweden
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Competitive Scenario
    • 8.5.8.3. Regulatory Framework
    • 8.5.8.4. Sweden Clinical Trial Supplies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.9. Norway
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Competitive Scenario
    • 8.5.9.3. Regulatory Framework
    • 8.5.9.4. Norway Clinical Trial Supplies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific Clinical Trial Supplies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.2. China
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. China Clinical Trial Supplies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.3. Japan
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Japan Clinical Trial Supplies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Competitive Scenario
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. India Clinical Trial Supplies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.5. Australia
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Competitive Scenario
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Australia Clinical Trial Supplies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.6. South Korea
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Competitive Scenario
    • 8.6.6.3. Regulatory Framework
    • 8.6.6.4. South Korea Clinical Trial Supplies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Competitive Scenario
    • 8.6.7.3. Regulatory Framework
    • 8.6.7.4. Thailand Clinical Trial Supplies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America Clinical Trial Supplies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. Brazil Clinical Trial Supplies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Argentina Clinical Trial Supplies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.8. Middle East and Africa
  • 8.8.1. Middle East and Africa Clinical Trial Supplies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Competitive Scenario
    • 8.8.2.3. Regulatory Framework
    • 8.8.2.4. South Africa Clinical Trial Supplies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Competitive Scenario
    • 8.8.3.3. Regulatory Framework
    • 8.8.3.4. Saudi Arabia Clinical Trial Supplies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Competitive Scenario
    • 8.8.4.3. Regulatory Framework
    • 8.8.4.4. UAE Clinical Trial Supplies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Competitive Scenario
    • 8.8.5.3. Regulatory Framework
    • 8.8.5.4. Kuwait Clinical Trial Supplies Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
  • 9.1.1. Market Leaders
  • 9.1.2. Emerging Players
• 9.2. Company Profiles
  • 9.2.1. Almac Group
    • 9.2.1.1. Participant's Overview
    • 9.2.1.2. Financial Performance
    • 9.2.1.3. Service Benchmarking
    • 9.2.1.4. Strategic Initiatives
  • 9.2.2. Biocair
    • 9.2.2.1. Participant's Overview
    • 9.2.2.2. Financial Performance
    • 9.2.2.3. Service Benchmarking
    • 9.2.2.4. Strategic Initiatives
  • 9.2.3. Catalent, Inc.
    • 9.2.3.1. Participant's Overview
    • 9.2.3.2. Financial Performance
    • 9.2.3.3. Service Benchmarking
    • 9.2.3.4. Strategic Initiatives
  • 9.2.4. KLIFO
    • 9.2.4.1. Participant's Overview
    • 9.2.4.2. Financial Performance
    • 9.2.4.3. Service Benchmarking
    • 9.2.4.4. Strategic Initiatives
  • 9.2.5. Movianto
    • 9.2.5.1. Participant's Overview
    • 9.2.5.2. Financial Performance
    • 9.2.5.3. Service Benchmarking
    • 9.2.5.4. Strategic Initiatives
  • 9.2.6. PCI Pharma Services
    • 9.2.6.1. Participant's Overview
    • 9.2.6.2. Financial Performance
    • 9.2.6.3. Service Benchmarking
    • 9.2.6.4. Strategic Initiatives
  • 9.2.7. Sharp Services, LLC
    • 9.2.7.1. Participant's Overview
    • 9.2.7.2. Financial Performance
    • 9.2.7.3. Service Benchmarking
    • 9.2.7.4. Strategic Initiatives
  • 9.2.8. Thermo Fisher Scientific, Inc.
    • 9.2.8.1. Participant's Overview
    • 9.2.8.2. Financial Performance
    • 9.2.8.3. Service Benchmarking
    • 9.2.8.4. Strategic Initiatives
  • 9.2.9. UPS Healthcare
    • 9.2.9.1. Participant's Overview
    • 9.2.9.2. Financial Performance
    • 9.2.9.3. Service Benchmarking
    • 9.2.9.4. Strategic Initiatives
  • 9.2.10. Paraxel International Corporation
    • 9.2.10.1. Participant's Overview
    • 9.2.10.2. Financial Performance
    • 9.2.10.3. Service Benchmarking
    • 9.2.10.4. Strategic Initiatives

관련자료